Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months
- 6 March 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 25 (5), 1633-1642
- https://doi.org/10.1007/s00198-014-2673-x
Abstract
In vitro data suggest that myokine irisin may affect bone metabolism by promoting osteoblast differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels were associated with previous osteoporotic fractures but not with bone mass and were not affected by denosumab or teriparatide treatment for 3 months.Keywords
This publication has 17 references indexed in Scilit:
- Irisin in humans: recent advances and questions for future researchMetabolism, 2014
- Exercise and bone: where do we stand?Metabolism, 2013
- Inducible Brown Adipose Tissue, or Beige Fat, Is Anabolic for the SkeletonEndocrinology, 2013
- Irisin: A renaissance in metabolism?Metabolism, 2013
- Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisClinical Endocrinology, 2013
- FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exerciseMetabolism, 2012
- Muscles, exercise and obesity: skeletal muscle as a secretory organNature Reviews Endocrinology, 2012
- Circulating 25-Hydroxyvitamin D Levels and Frailty Status in Older WomenJournal of Clinical Endocrinology & Metabolism, 2010
- OsteoporosisThe Lancet, 2006
- Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its UseEndocrine Reviews, 2005